JPH10509143A - 2,2′−ジチオ−ビス(エタンスルホネート)(ジメスナ)と組み合わせたシスプラチン組成物 - Google Patents
2,2′−ジチオ−ビス(エタンスルホネート)(ジメスナ)と組み合わせたシスプラチン組成物Info
- Publication number
- JPH10509143A JPH10509143A JP8515745A JP51574596A JPH10509143A JP H10509143 A JPH10509143 A JP H10509143A JP 8515745 A JP8515745 A JP 8515745A JP 51574596 A JP51574596 A JP 51574596A JP H10509143 A JPH10509143 A JP H10509143A
- Authority
- JP
- Japan
- Prior art keywords
- cisplatin
- bis
- dithio
- composition
- ethanesulfonate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.ガン患者への投与に適した組成物であって、シスプラチンおよび薬学的許容 形態にある2,2’−ジチオ−ビス(エタンスルホネート)からなることを特徴 とする組成物。 2.pH値が 2ないし 6の無菌注射可能水溶液または懸濁液の形態であることを特 徴とする請求項1記載の組成物。 3.pH値が 4ないし 6であることを特徴とする請求項2記載の組成物。 4.緩衝剤を含むことを特徴とする請求項2または3記載の組成物。 5.塩素陰イオンならびにナトリウムおよび水素陽イオンを含むことを特徴とす る請求項2、3または4記載の組成物。 6.0.1 ないし1.0 mg/mlのシスプラチン、1.0 ないし 320 mg/mlのスルホネー トならびに 10 ないし 25 mg/ml の塩化ナトリウムおよび塩酸またはリン酸を含 むことを特徴とする請求項5記載の組成物。 7.10ないし 25 mg/ml のマンニトールを含むことを特徴とする請求項6記載の 組成物。 8.親液体の形態にあることを特徴とする請求項1、2、3、4、5、6または 7記載の組成物。 9.2,2’−ジチオ−ビス(エタンスルホネート)をシ スプラチンとの組み合わせで患者に実質的に同時かまたは続けて投与し、該シス プラチンと該スルホネートとが患者の血液中に共存するようになることを特徴と する医薬品の調合への2,2’−ジチオ−ビス(エタンスルホネート)の使用。 10.スルホネートの水溶液が親液性化形態にあることを特徴とする請求項9記載 の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/338,379 US5789000A (en) | 1994-11-14 | 1994-11-14 | Sterile aqueous parenteral formulations of cis-diammine dichloro platinum |
US08/338,379 | 1994-11-14 | ||
PCT/EP1995/004490 WO1996014852A1 (en) | 1994-11-14 | 1995-11-14 | Composition of cisplatin in combination with 2,2'-dithio-bis(ethanesulfonate) (dimesna) |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008047977A Division JP2008133304A (ja) | 1994-11-14 | 2008-02-28 | 2,2’−ジチオ−ビス(エタンスルホネート)(ジメスナ)と組み合わせたシスプラチン組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH10509143A true JPH10509143A (ja) | 1998-09-08 |
JP4171526B2 JP4171526B2 (ja) | 2008-10-22 |
Family
ID=23324592
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51574596A Expired - Fee Related JP4171526B2 (ja) | 1994-11-14 | 1995-11-14 | 2,2′−ジチオ−ビス(エタンスルホネート)(ジメスナ)と組み合わせたシスプラチン組成物 |
JP2008047977A Pending JP2008133304A (ja) | 1994-11-14 | 2008-02-28 | 2,2’−ジチオ−ビス(エタンスルホネート)(ジメスナ)と組み合わせたシスプラチン組成物 |
JP2012172119A Pending JP2012211198A (ja) | 1994-11-14 | 2012-08-02 | 2,2’−ジチオ−ビス(エタンスルホネート)(ジメスナ)と組み合わせたシスプラチン組成物 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008047977A Pending JP2008133304A (ja) | 1994-11-14 | 2008-02-28 | 2,2’−ジチオ−ビス(エタンスルホネート)(ジメスナ)と組み合わせたシスプラチン組成物 |
JP2012172119A Pending JP2012211198A (ja) | 1994-11-14 | 2012-08-02 | 2,2’−ジチオ−ビス(エタンスルホネート)(ジメスナ)と組み合わせたシスプラチン組成物 |
Country Status (13)
Country | Link |
---|---|
US (5) | US5789000A (ja) |
EP (1) | EP0792154B1 (ja) |
JP (3) | JP4171526B2 (ja) |
KR (1) | KR100411380B1 (ja) |
CN (2) | CN1165483B (ja) |
AT (1) | ATE237337T1 (ja) |
AU (1) | AU706181B2 (ja) |
CA (1) | CA2202170C (ja) |
DE (1) | DE69530412T2 (ja) |
DK (1) | DK0792154T3 (ja) |
ES (1) | ES2191717T3 (ja) |
PT (1) | PT792154E (ja) |
WO (1) | WO1996014852A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006513190A (ja) * | 2002-12-21 | 2006-04-20 | バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド | 有毒化学試薬に曝露した患者の処置方法 |
JP2008513503A (ja) * | 2004-09-21 | 2008-05-01 | バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド | 医薬用ジスルフィド塩 |
JP2010531877A (ja) * | 2007-06-27 | 2010-09-30 | ポニアード ファーマシューティカルズ, インコーポレイテッド | 安定化したピコプラチン投与形態 |
JP2011514356A (ja) * | 2008-03-14 | 2011-05-06 | バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド | 化学的保護方法及び組成物 |
JP2011514355A (ja) * | 2008-03-14 | 2011-05-06 | バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド | 肺癌、腺癌及び他の病状のための治療方法及び組成物 |
US8710095B2 (en) | 2002-04-30 | 2014-04-29 | Bionumerik Pharmaceuticals, Inc. | Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5789000A (en) * | 1994-11-14 | 1998-08-04 | Bionumerik Pharmaceuticals, Inc. | Sterile aqueous parenteral formulations of cis-diammine dichloro platinum |
US6025488A (en) * | 1994-11-14 | 2000-02-15 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
US5919816A (en) * | 1994-11-14 | 1999-07-06 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
US6037336A (en) * | 1996-09-23 | 2000-03-14 | Bionumerik Pharmaceuticals, Inc. | Reducing toxic effects of carboplatin using dithioethers |
ES2170414T3 (es) * | 1996-09-23 | 2002-08-01 | Bionumerik Pharmaceuticals Inc | Reduccion de efectos toxicos del carboplatino usando ditioeteres. |
US20070142267A1 (en) * | 1998-11-23 | 2007-06-21 | Novelos Therapeutics, Inc. | Methods for production of the oxidized glutathione composite with CIS-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells |
US6312734B1 (en) * | 1998-11-23 | 2001-11-06 | Novelos Therapeutics, Inc. | Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells |
RU2144374C1 (ru) * | 1998-11-23 | 2000-01-20 | Закрытое акционерное общество "ВАМ" | Способ получения композита окисленного глутатиона с cis-диаминодихлорплатиной и фармацевтических композиций на его основе, регулирующих метаболизм, пролиферацию, дифференцировку и механизмы апоптоза нормальных и трансформированных клеток |
US6197831B1 (en) * | 1999-02-09 | 2001-03-06 | Bionumerik Pharmaceuticals, Inc. | Method of treating septic shock |
US6034126A (en) * | 1999-05-24 | 2000-03-07 | Bionumerik Pharmaceuticals, Inc. | Method for treating glycol poisoning |
CA2385528C (en) | 1999-10-01 | 2013-12-10 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
US6156350A (en) * | 1999-12-02 | 2000-12-05 | Corazon Technologies, Inc. | Methods and kits for use in preventing restenosis |
AU5391901A (en) | 2000-04-26 | 2001-11-07 | Univ Oregon Health Sciences | Administration of a thiol-based chemoprotectant compound |
GB0011903D0 (en) * | 2000-05-18 | 2000-07-05 | Astrazeneca Ab | Combination chemotherapy |
US7211562B2 (en) * | 2000-11-02 | 2007-05-01 | Sloan-Kettering Institute For Cancer Research | Methods for enhancing the efficacy of cytotoxic agents through the use of HSP90 inhibitors |
US6540733B2 (en) * | 2000-12-29 | 2003-04-01 | Corazon Technologies, Inc. | Proton generating catheters and methods for their use in enhancing fluid flow through a vascular site occupied by a calcified vascular occlusion |
CA2434270A1 (en) * | 2001-01-19 | 2002-07-25 | Bionumerik Pharmaceuticals, Inc. | Use of mesna compounds to prevent adverse reactions to anti-neoplastic compositions |
US20030091574A1 (en) * | 2001-03-23 | 2003-05-15 | Gevas Philip C. | Combination treatment of pancreatic cancer |
US20090191232A1 (en) * | 2001-05-04 | 2009-07-30 | Gevas Philip C | Combination therapy for the treatment of tumors |
CA2450898A1 (en) * | 2001-07-09 | 2003-01-23 | Aphton Corporation | Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus |
US6352979B1 (en) * | 2001-08-20 | 2002-03-05 | Lucinda Lizcano | Method of treating snakebite and complications resulting therefrom |
EA007481B1 (ru) * | 2001-09-24 | 2006-10-27 | Тоск, Инк. | Цисплатиновые составы пониженной токсичности и способы их применения |
US7176192B2 (en) * | 2001-10-26 | 2007-02-13 | Bionumerik Pharmaceuticals, Inc. | Method for treating patients for radiation exposure |
US6596320B1 (en) * | 2002-01-11 | 2003-07-22 | Bionumerik Pharmaceuticals, Inc. | Method for treating cancer having greater efficacy and reduced adverse effects |
EP1534854A4 (en) * | 2002-03-28 | 2006-11-15 | Ohio Med College | METHOD AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF NON-SMALL CELL LUNG CANCER USING GENE EXPRESSION PROFILES |
US20040014730A1 (en) * | 2002-07-10 | 2004-01-22 | Frederick Hausheer | Formulations and methods of reducing toxicity of anti-infective agents |
JP2006521377A (ja) | 2003-03-27 | 2006-09-21 | ランケナー インスティテュート フォー メディカル リサーチ | 新型ido阻害剤とその使用方法 |
US20060020119A1 (en) * | 2004-03-29 | 2006-01-26 | Stephen Grimes | Monoclonal antibodies to gastrin hormone |
CN100450999C (zh) * | 2003-12-17 | 2009-01-14 | 比奥纽默里克药物公司 | 合成二硫化物的方法 |
US20050256055A1 (en) * | 2004-05-12 | 2005-11-17 | Hausheer Frederick H | Compounds and methods for reducing undesired toxicity of chemotherapeutic agents |
US20090111735A1 (en) * | 2004-05-12 | 2009-04-30 | Bionumerik Pharmaceuticals, Inc. | Compounds and methods for reducing undesired toxicity of chemotherapeutic agents |
US7235589B2 (en) | 2004-09-21 | 2007-06-26 | Bio Numerik Pharmaceuticals, Inc. | Method of treating patients undergoing kidney dialysis |
US20060063742A1 (en) * | 2004-09-21 | 2006-03-23 | Hausheer Frederick H | Method of treatment for or protection against lymphedema |
JP2008513536A (ja) | 2004-09-22 | 2008-05-01 | レセプター バイオロジックス インコーポレイテッド | プロガストリンに対するモノクローナル抗体 |
CN100443081C (zh) * | 2005-04-05 | 2008-12-17 | 吴一心 | 木犀草素与一种铂类化疗药物联合用于制备抗肿瘤的药物 |
CA2631760A1 (en) * | 2005-12-02 | 2007-06-07 | Robert A. Brodsky | Use of high-dose oxazaphosphorine drugs for treating immune disorders |
DK1991237T3 (en) * | 2005-12-13 | 2015-04-27 | Bionumerik Pharmaceuticals Inc | Chemoprotective methods and compositions |
US20070219268A1 (en) * | 2006-03-16 | 2007-09-20 | Bionumerik Pharmaceuticals, Inc. | Anti-cancer activity augmentation compounds and formulations and methods of use thereof |
WO2008034074A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Cyclosphosphamide in combination with anti-idiotypic vaccines |
WO2008034076A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Cyclophosphamide in combination with immune therapeutics |
WO2008034071A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Method of identifying patients suitable for high-dose cyclophosphamide treatment |
WO2008097658A1 (en) * | 2007-02-09 | 2008-08-14 | Poniard Pharmaceuticals, Inc. | Encapsulated picoplatin |
US20100310661A1 (en) * | 2007-07-16 | 2010-12-09 | Poniard Pharmaceuticals, Inc. | Oral formulations for picoplatin |
WO2009039190A1 (en) * | 2007-09-17 | 2009-03-26 | Gene Express, Inc. | Cancer risk biomarker |
WO2009067699A2 (en) * | 2007-11-21 | 2009-05-28 | Accentia Biopharmaceuticals, Inc. | Methods for providing a system of care for an oxazaphosphorine drug regimen |
US9026372B2 (en) * | 2007-11-21 | 2015-05-05 | Accentia Biopharmaceuticals, Inc. | Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen |
AU2009210734A1 (en) * | 2008-02-08 | 2009-08-13 | Poniard Pharmaceuticals, Inc. | Picoplatin and amrubicin to treat lung cancer |
US9320760B2 (en) * | 2008-03-14 | 2016-04-26 | Bionumerik Pharmaceuticals, Inc. | Compositions and methods of use of compounds to increase cancer patient survival time |
CN102014891B (zh) * | 2008-03-14 | 2013-12-18 | 比奥纽默里克药物公司 | 增加癌症患者存活时间的化合物的组合物和使用方法 |
US20110064828A1 (en) * | 2009-09-11 | 2011-03-17 | Novelos Therapeutics, Incorporated | Treatment of metastatic tumors and other conditions |
TWI438009B (zh) * | 2010-02-19 | 2014-05-21 | Teikoku Pharma Usa Inc | 紫杉烷前-乳劑調配物及其製造與使用之方法 |
MY167224A (en) | 2010-05-03 | 2018-08-14 | Teikoku Pharma Usa Inc | Non-Aqueous Taxane Pro-Emulsion Formulations and Methods of Making and Using the Same |
CN115778934A (zh) * | 2012-01-20 | 2023-03-14 | 德玛公司 | 经取代的己糖醇类用于治疗恶性肿瘤的用途 |
CN110051686A (zh) * | 2012-07-19 | 2019-07-26 | 瑞立普萨公司 | 包含交联阳离子结合聚合物的组合物 |
JO3685B1 (ar) | 2012-10-01 | 2020-08-27 | Teikoku Pharma Usa Inc | صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها |
AU2018283284B2 (en) | 2017-06-15 | 2024-05-16 | Cancer Advances Inc. | Compositions and methods for inducing humoral and cellular immunities against tumors and cancer |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2806866C3 (de) * | 1978-02-17 | 1981-02-12 | Asta-Werke Ag Chemische Fabrik, 4800 Bielefeld | Verwendung von Salzen von Dithiodialkansulfonsäuren |
US4310515A (en) * | 1978-05-30 | 1982-01-12 | Bristol-Myers Company | Pharmaceutical compositions of cisplatin |
ES2040394T3 (es) * | 1988-03-19 | 1993-10-16 | Asta Medica Aktiengesellschaft | Procedimiento para preparar un material liofilizado de ifosfamida y mesna. |
US5227373A (en) * | 1991-10-23 | 1993-07-13 | Bristol-Myers Squibb Co. | Lyophilized ifosfamide compositions |
JP3954115B2 (ja) * | 1992-07-28 | 2007-08-08 | アストラゼネカ・アクチエボラーグ | 注射剤および注射剤キット |
US5789000A (en) * | 1994-11-14 | 1998-08-04 | Bionumerik Pharmaceuticals, Inc. | Sterile aqueous parenteral formulations of cis-diammine dichloro platinum |
-
1994
- 1994-11-14 US US08/338,379 patent/US5789000A/en not_active Expired - Lifetime
-
1995
- 1995-11-03 US US08/553,005 patent/US5902610A/en not_active Expired - Lifetime
- 1995-11-14 CN CN951962310A patent/CN1165483B/zh not_active Expired - Lifetime
- 1995-11-14 WO PCT/EP1995/004490 patent/WO1996014852A1/en not_active Application Discontinuation
- 1995-11-14 PT PT95939282T patent/PT792154E/pt unknown
- 1995-11-14 EP EP95939282A patent/EP0792154B1/en not_active Expired - Lifetime
- 1995-11-14 JP JP51574596A patent/JP4171526B2/ja not_active Expired - Fee Related
- 1995-11-14 CA CA002202170A patent/CA2202170C/en not_active Expired - Lifetime
- 1995-11-14 CN CN2010102328968A patent/CN101987111A/zh active Pending
- 1995-11-14 ES ES95939282T patent/ES2191717T3/es not_active Expired - Lifetime
- 1995-11-14 AU AU41168/96A patent/AU706181B2/en not_active Expired
- 1995-11-14 KR KR1019970703171A patent/KR100411380B1/ko active IP Right Grant
- 1995-11-14 AT AT95939282T patent/ATE237337T1/de active
- 1995-11-14 DK DK95939282T patent/DK0792154T3/da active
- 1995-11-14 DE DE69530412T patent/DE69530412T2/de not_active Expired - Lifetime
-
1997
- 1997-04-18 US US08/844,544 patent/US5866617A/en not_active Expired - Lifetime
- 1997-04-30 US US08/848,361 patent/US5866615A/en not_active Expired - Lifetime
- 1997-06-18 US US08/878,244 patent/US5866169A/en not_active Expired - Lifetime
-
2008
- 2008-02-28 JP JP2008047977A patent/JP2008133304A/ja active Pending
-
2012
- 2012-08-02 JP JP2012172119A patent/JP2012211198A/ja active Pending
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8710095B2 (en) | 2002-04-30 | 2014-04-29 | Bionumerik Pharmaceuticals, Inc. | Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity |
JP2006513190A (ja) * | 2002-12-21 | 2006-04-20 | バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド | 有毒化学試薬に曝露した患者の処置方法 |
JP2008513503A (ja) * | 2004-09-21 | 2008-05-01 | バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド | 医薬用ジスルフィド塩 |
JP2010531877A (ja) * | 2007-06-27 | 2010-09-30 | ポニアード ファーマシューティカルズ, インコーポレイテッド | 安定化したピコプラチン投与形態 |
JP2011514356A (ja) * | 2008-03-14 | 2011-05-06 | バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド | 化学的保護方法及び組成物 |
JP2011514355A (ja) * | 2008-03-14 | 2011-05-06 | バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド | 肺癌、腺癌及び他の病状のための治療方法及び組成物 |
Also Published As
Publication number | Publication date |
---|---|
CN1165483B (zh) | 2012-09-05 |
US5902610A (en) | 1999-05-11 |
CN1165483A (zh) | 1997-11-19 |
US5789000A (en) | 1998-08-04 |
CA2202170C (en) | 2007-04-10 |
US5866615A (en) | 1999-02-02 |
JP2012211198A (ja) | 2012-11-01 |
US5866169A (en) | 1999-02-02 |
WO1996014852A1 (en) | 1996-05-23 |
DK0792154T3 (da) | 2003-08-04 |
CN101987111A (zh) | 2011-03-23 |
ES2191717T3 (es) | 2003-09-16 |
CA2202170A1 (en) | 1996-05-23 |
KR100411380B1 (ko) | 2004-04-30 |
EP0792154A1 (en) | 1997-09-03 |
AU706181B2 (en) | 1999-06-10 |
US5866617A (en) | 1999-02-02 |
DE69530412D1 (de) | 2003-05-22 |
PT792154E (pt) | 2003-09-30 |
DE69530412T2 (de) | 2003-10-30 |
JP4171526B2 (ja) | 2008-10-22 |
KR970706830A (ko) | 1997-12-01 |
ATE237337T1 (de) | 2003-05-15 |
JP2008133304A (ja) | 2008-06-12 |
EP0792154B1 (en) | 2003-04-16 |
MX9703460A (es) | 1997-07-31 |
AU4116896A (en) | 1996-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4171526B2 (ja) | 2,2′−ジチオ−ビス(エタンスルホネート)(ジメスナ)と組み合わせたシスプラチン組成物 | |
US8247398B2 (en) | Zinc complexes of natural amino acids for treating elevated copper caused toxicities | |
AU2002352105B2 (en) | Platinum derivative pharmaceutical formulations | |
US5883088A (en) | Solid dosage forms for the oral administration of gallium | |
US20100240601A1 (en) | Coordination Complexes, Pharmaceutical Solutions Comprising Coordination Complexes, and Methods of Treating Patients | |
US5574027A (en) | Pharmaceutical compositions of gallium complexes of 3-hydroxy-4-pyrones | |
JPH06501000A (ja) | グルタミンを用いるグルタチオンレベルの増大法 | |
JP2009143950A (ja) | ジチオエーテルを用いたカルボプラチンの毒減少効果 | |
JP2009143950A6 (ja) | ジチオエーテルを用いたカルボプラチンの毒減少効果 | |
JPH10507162A (ja) | 7−ハロ−1,2,3,4−テトラヒドロ−3−アリール−6−キナゾリン スルホンアミドを含有する非経口溶液 | |
US6037336A (en) | Reducing toxic effects of carboplatin using dithioethers | |
EP0612246B1 (en) | Pharmaceutical compositions of gallium complexes of 3-hydroxy-4-pyrones | |
TWI316403B (en) | Glycyrrhizin containing pharmaceutical composition | |
MXPA97003460A (en) | Composition of cisplatine in combination with 2,2'ditio-bis (ethanosulphonate) (dimes) | |
JPS6054320A (ja) | 腎疾患治療剤 | |
JPH07126167A (ja) | 腎疾患治療剤および人工腎臓用透析液 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20040817 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041203 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20061212 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070309 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070507 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070608 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20070608 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070828 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071121 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080111 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071226 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080208 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080125 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080303 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080228 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080507 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080604 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080805 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080811 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110815 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110815 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120815 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130815 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |